Featured Survivor Story:
![Image](https://www.aimatmelanoma.org/wp-content/uploads/Big-Text-How-to-Youtube-Thumbnail-1.jpg)
June marks National Cancer Survivor Month, a time to honor the remarkable resilience and strength of those who have battled and continue to battle melanoma. In this special digital magazine, we feature three inspiring melanoma survivors. Their stories exemplify the power of hope, community, and perseverance.
If you’re a melanoma survivor, know that you’re not alone. Reach out, share your story, and connect with others who understand your experience. Together, we can continue to support and uplift each other.
For more information and resources, consider getting involved with our foundation. Let’s make a difference, one story at a time.
Reach out to Ann Garst Taylor, our Director of Community Engagement, to explore opportunities for involvement!
Email Ann: Engageus@AIMatMelanoma.org
Recent Posts
![Featured image for “Summary of Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma”](https://www.aimatmelanoma.org/wp-content/uploads/new-arrival-4-150x150.jpg)
Summary of Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
![Featured image for “In Plain English: Overview of the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO)”](https://www.aimatmelanoma.org/wp-content/uploads/new-arrival-3-150x150.jpg)
In Plain English: Overview of the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO)
![Featured image for “Stories of Strength: Three Melanoma Survivors Who Inspire Us All”](https://www.aimatmelanoma.org/wp-content/uploads/Big-Text-How-to-Youtube-Thumbnail-1-150x150.jpg)
Stories of Strength: Three Melanoma Survivors Who Inspire Us All
![Featured image for “World Health Organization Predicts Half a Million With Melanoma in 2040”](https://www.aimatmelanoma.org/wp-content/uploads/Pink-and-Purple-Minimalist-Online-Yoga-Youtube-Channel-Art-90-150x150.jpg)
World Health Organization Predicts Half a Million With Melanoma in 2040
![Featured image for “Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma”](https://www.aimatmelanoma.org/wp-content/uploads/Blogging-Tips-LinkedIn-Post-Header-83-150x150.jpg)